Cd49d is disease progression biomarker in duchenne muscular dystrophy

HIGHLIGHTS

• who: Pinto-Mariz et_al Skeletal Muscle et al. from the slow progression, n=15, respectively)A control group (n=14) comprised age-/sex-matched healthy volunteers. We also developed a prospective study of CD49d levels on T cells in DMD patients who were able to walk at a speed ≤, m/s and were followed until they lost their ability to walk. If such a loss occurred before , years of age, this was considered rapid progression, whereas after , years of age, it was considered slow progression. We also evaluated biopsies from DMD patients who had lost ambulation before . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.